Pulse nav.journalClub Débats actifs Tendances Explorer Chercheurs

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Accueil Explorer nav.journalClub Tendances

⌘+K

© Synapse Social LLC, 2026

Politique de confidentialité

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances | Synapse

June 29, 2022Open Access

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances

Key Points

Key points are not available for this paper at this time.

Abstract

Nemolizumab has a rapid and robust onset of action in PN with itch reduction and improvement of sleep within 48 h.

Read Full Paperexternally

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Cite This Study

Ständer et al. (Wed,) studied this question.

synapsesocial.com/papers/69da7db10f32475823a3d5ab https://doi.org/https://doi.org/10.1111/jdv.18377

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The self‐assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries2018 · 83 citations
2Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus2019 · 272 citations
3Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial2019 · 113 citations
4<p>Treatment-resistant prurigo nodularis: challenges and solutions</p>2019 · 49 citations
5Emerging novel therapeutic agents for the treatment of patients with prurigo nodularis2020 · 9 citations